{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:31:18Z","timestamp":1791228678449,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.clml.2013.04.003","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T16:15:44Z","timestamp":1370880944000},"page":"351-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Efficacy and Management of Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"13","author":[{"given":"Bertrand","family":"Coiffier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.04.003_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.critrevonc.2011.05.001","article-title":"Mantle cell lymphoma","volume":"82","author":"Cortelazzo","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2013.04.003_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3109\/10428194.2012.733882","article-title":"Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network","volume":"54","author":"Dreyling","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.04.003_bib3","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/cncr.25756","article-title":"Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma","volume":"117","author":"Dietrich","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.04.003_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib5","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib6","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.04.003_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.04.003_bib8","volume":"116","author":"Hermine","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.04.003_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.seminhematol.2011.06.002","article-title":"Treatment of younger patients with mantle cell lymphoma","volume":"48","author":"Harel","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2013.04.003_bib10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.04.003_bib11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1586\/ehm.09.57","article-title":"Temsirolimus for the treatment of mantle cell lymphoma","volume":"2","author":"Hess","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2013.04.003_bib12","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib13","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.04.003_bib16","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib17","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib18","doi-asserted-by":"crossref","first-page":"435342","DOI":"10.1155\/2012\/435342","article-title":"The role of mTOR inhibitors for the treatment of B-cell lymphomas","volume":"2012","author":"Argyriou","year":"2012","journal-title":"Adv Hematol"},{"key":"10.1016\/j.clml.2013.04.003_bib19","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3109\/10428190903207548","article-title":"Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies","volume":"50","author":"Coiffier","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.04.003_bib20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1634\/theoncologist.2010-0318","article-title":"Utility of mTOR inhibition in hematologic malignancies","volume":"16","author":"Younes","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2013.04.003_bib21","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","article-title":"The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy","volume":"13","author":"Abraham","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.04.003_bib22","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1158\/0008-5472.CAN-07-6487","article-title":"A\u00a0new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis","volume":"68","author":"Shor","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.04.003_bib23","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","article-title":"Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus","volume":"66","author":"Del Bufalo","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.04.003_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.04.003_bib25","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.04.003_bib26","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.2353\/ajpath.2006.051078","article-title":"Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma","volume":"169","author":"Peponi","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2013.04.003_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1756-8722-3-30","article-title":"Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma","volume":"3","author":"Wang","year":"2010","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.exphem.2007.12.008","article-title":"Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma","volume":"36","author":"Yazbeck","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2013.04.003_bib29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.04.003_bib30","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.1998.16.2.579","article-title":"Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas","volume":"16","author":"Decaudin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib32","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.2001.02795.x","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma","volume":"113","author":"Dumontet","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.04.003_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2005.03.9313","article-title":"Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma","volume":"24","author":"Tobinai","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib35","doi-asserted-by":"crossref","unstructured":"Hess G, Keller U, Atta J, et\u00a0al. Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report on an ongoing phase I\/II trial. Presented at: Annual Meeting of the American Society of Hematology; December 10-13, 2011; San Diego, CA. Abstract\u00a02697.","DOI":"10.1182\/blood.V118.21.2697.2697"},{"key":"10.1016\/j.clml.2013.04.003_bib36","unstructured":"Torisel [annex 1 summary of product characteristics]. European Medicines Agency.\u00a0Available at: www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000799\/WC500039912.pdf. Accessed October 18,\u00a02011."},{"key":"10.1016\/j.clml.2013.04.003_bib37","unstructured":"Hess G, Kang L, Moran PJ. Temsirolimus in patients with relapsed\/refractory mantle cell lymphoma: does prognostic risk affect outcomes? Presented at: 17th Congress of the European Hematology Association; Amsterdam, The Netherlands; June 14-17, 2012. Abstract 0250."},{"key":"10.1016\/j.clml.2013.04.003_bib38","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.04.003_bib39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.04.003_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.tps222","article-title":"Randomized phase IV trial comparing efficacy and tolerability of temsirolimus with and without an elevated starting dose in patients with relapsed, refractory mantle cell lymphoma","volume":"29","author":"Bair","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib41","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1124\/dmd.107.014746","article-title":"In\u00a0vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites","volume":"35","author":"Cai","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clml.2013.04.003_bib42","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1177\/0091270007306957","article-title":"Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications","volume":"47","author":"Boni","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clml.2013.04.003_bib43","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/sj.bjc.6604376","article-title":"Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus","volume":"98","author":"Boni","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2013.04.003_bib44","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1053\/j.seminoncol.2009.10.009","article-title":"Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations","volume":"36","author":"Boni","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00280-008-0865-9","article-title":"Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus","volume":"64","author":"Boni","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2013.04.003_bib46","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.transproceed.2011.06.060","article-title":"Sirolimus-induced pneumonitis complicated by pentamidine-induced phospholipidosis in a renal transplant recipient: a case report","volume":"43","author":"Filippone","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.clml.2013.04.003_bib47","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.04.003_bib48","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1200\/JCO.2010.29.2235","article-title":"Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus","volume":"29","author":"Maroto","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib49","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-11-3152","article-title":"New strategies in the treatment of mantle cell lymphoma","volume":"18","author":"Deng","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.04.003_bib50","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.beha.2012.04.001","article-title":"Novel agents in mantle cell lymphoma","volume":"25","author":"Noel","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2013.04.003_bib51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.semcancer.2011.09.008","article-title":"New molecular targets in mantle cell lymphoma","volume":"21","author":"Parekh","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clml.2013.04.003_bib52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.beha.2012.04.008","article-title":"Targeting mTOR in mantle cell lymphoma: current and future directions","volume":"25","author":"Smith","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2013.04.003_bib53","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of\u00a0rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.04.003_bib54","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A\u00a0multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.04.003_bib55","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.04.003_bib56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.04.003_bib57","doi-asserted-by":"crossref","unstructured":"Papadopoulis KP, Abrisqueta P, Chambers G, et\u00a0al. A phase I dose expansion cohort study of the safety, pharmacokinetics and pharmacodynamics of SAR245409 (S09), an orally administered PI3K\/mTOR inhibitor, in patients with lymphoma. Presented at: 53rd American Society of Hematology Annual Meeting; December 10-13, 2011. San Diego, CA. Abstract\u00a01608.","DOI":"10.1182\/blood.V118.21.1608.1608"},{"key":"10.1016\/j.clml.2013.04.003_bib58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.04.003_bib59","doi-asserted-by":"crossref","unstructured":"Wang L, Martin P, Blum KA, et\u00a0al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Presented at: 53rd American Society of Hematology Annual Meeting; December 10-13, 2011; San Diego, CA. Abstract\u00a0442.","DOI":"10.1182\/blood.V118.21.442.442"},{"key":"10.1016\/j.clml.2013.04.003_bib60","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.leukres.2012.02.010","article-title":"The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells","volume":"36","author":"Kim","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2013.04.003_bib61","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1158\/1078-0432.CCR-12-0351","article-title":"Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma","volume":"18","author":"Rosich","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.04.003_bib62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4137\/CMO.S7327","article-title":"Relapsed and\/or refractory mantle cell lymphoma: what role for temsirolimus?","volume":"6","author":"Kirschey","year":"2012","journal-title":"Clin Med Insights Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:11Z","timestamp":1761870311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013001043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S2152265013001043"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.04.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Efficacy and Management of Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}